Sidley Advises HJ Science on Its Successful Chapter 18A Listing in Hong Kong

Sidley acted as Hong Kong and U.S. counsel to HJ Science Co., Ltd. (HJ Science) (HKEX: 6132) in its initial public offering (IPO) and H share listing on the Main Board of the Hong Kong Stock Exchange (HKEX), under Chapter 18A of the Hong Kong Listing Rules. The offering raised approximately HK$1.11 billion (US$142 million). CITIC Securities (Hong Kong) Limited acted as the sole sponsor in the transaction.

HJ Science is a clinical-stage biotech company founded by a team of industrial experts in 2017, dedicated to researching and developing differentiated innovative small-molecule drugs for autoimmune, metabolic, and oncology disease.

The Sidley team was led by partners Claudia Yu and Meng Ding (China Corporate and Finance). Other team members included Liming Xu, Kevin Chan, Cleo Wang, Stark Liu, Rosie Tang, and John Lau (all China Corporate and Finance).

Sidley has been a market leader in advising life sciences and biotech IPOs in Hong Kong. It is the only Band One firm ranked by Chambers Greater China Region/Asia Pacific in life sciences for 16 consecutive years. Sidley has also been “highly recommended” in “Innovative Lawyers in Unlocking Capital” by the FT Innovative Lawyers APAC Awards in 2025, recognizing its contribution in “Reformed Listing Rules on the HKEX - revitalizing the Hong Kong IPO market.” Additionally, Sidley’s Capital Markets practice has also received a number of independent recognitions from publications such as The Asia Legal Awards by Law.com International, IFLR APAC Awards, China Business Law Journal, and Legal 500 APAC.